Physician profile
Ronald E Mccord
NPI 1295728053
$2,745.79
in general payments reported to CMS, 2019-2025
16 companies · $682 in 2025
The $682 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $356 · 2021: $350 · 2022: $287 · 2023: $305 · 2024: $250 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $526.41 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $511.39 | 2022-2025 | Acuvue |
| Alcon Vision LLC | $361.22 | 2025 | Precision7 |
| Optovue, INC. | $171.08 | 2019-2020 | |
| Glaukos Corporation | $127.12 | 2019 | |
| Kala Pharmaceuticals, INC. | $125.00 | 2020 | |
| Bausch & Lomb Americas INC. | $123.97 | 2023 | Infuse |
| Lkc Technologies, INC. | $122.50 | 2024-2025 | |
| Abbvie INC. | $115.99 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $110.83 | 2019 | |
| Dompe US, INC. | $102.89 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $89.46 | 2019 | |
| Coopervision INC. | $88.42 | 2021 | |
| Hoffmann-La Roche Limited | $79.54 | 2019 | |
| Visionix USA, INC | $74.99 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $14.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mccord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.